Lei Huang

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells
    Caining Jin
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 7:e39432. 2012
  2. pmc MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells
    Michio Kosugi
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 6:e28234. 2011
  3. pmc Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer
    Akriti Kharbanda
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Mol Cancer Res 11:714-23. 2013
  4. pmc MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches
    D W Kufe
    Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Oncogene 32:1073-81. 2013
  5. pmc MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients
    Dhara M Macdermed
    The Scripps Research Institute and Scripps Translational Science Institute, 3344 N Torrey Pines Court Ste, 300, La Jolla, CA 92037, USA
    BMC Med Genomics 3:16. 2010
  6. pmc Mucins in cancer: function, prognosis and therapy
    Donald W Kufe
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Rev Cancer 9:874-85. 2009
  7. pmc Oncogenic function of the MUC1 receptor subunit in gene regulation
    D Kufe
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Oncogene 29:5663-6. 2010
  8. ncbi request reprint Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology
    Donald Kufe
    Dana Farber Cancer Institute, Harvard Medical School Boston, Massachusetts USA
    Cancer Biol Ther 2:326-9. 2003
  9. ncbi request reprint Inhibition of c-Abl with STI571 attenuates stress-activated protein kinase activation and apoptosis in the cellular response to 1-beta-D-arabinofuranosylcytosine
    Deepak Raina
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Pharmacol 61:1489-95. 2002
  10. ncbi request reprint Targeting the human MUC1 oncoprotein: a tale of two proteins
    Donald W Kufe
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Biol Ther 7:81-4. 2008

Detail Information

Publications82

  1. pmc Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells
    Caining Jin
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 7:e39432. 2012
    ..These findings indicate that MUC1-C and Rab31 function in an autoinductive loop that contributes to overexpression of MUC1-C in breast cancer cells...
  2. pmc MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells
    Michio Kosugi
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 6:e28234. 2011
    ..Thus, the overexpression of MUC1-C oncoprotein in diverse human carcinomas could be of importance to the Warburg effect of aerobic glycolysis...
  3. pmc Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer
    Akriti Kharbanda
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Mol Cancer Res 11:714-23. 2013
    ..Moreover, we show that targeting MUC1-C in combination with tamoxifen is highly synergistic in the treatment of tamoxifen-resistant breast cancer cells. Combined, these findings indicate that MUC1-C contributes to tamoxifen resistance...
  4. pmc MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches
    D W Kufe
    Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Oncogene 32:1073-81. 2013
    ..On the basis of these findings, a first-in-class MUC1-C inhibitor has entered phase I evaluation as a potential agent for the treatment of patients with breast cancers who express this oncoprotein...
  5. pmc MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients
    Dhara M Macdermed
    The Scripps Research Institute and Scripps Translational Science Institute, 3344 N Torrey Pines Court Ste, 300, La Jolla, CA 92037, USA
    BMC Med Genomics 3:16. 2010
    ..The cytoplasmic domain of MUC1 (MUC1-CD) induces tumorigenesis and resistance to DNA-damaging agents. We characterized MUC1-CD-induced transcriptional changes and examined their significance in lung cancer patients...
  6. pmc Mucins in cancer: function, prognosis and therapy
    Donald W Kufe
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Rev Cancer 9:874-85. 2009
    ....
  7. pmc Oncogenic function of the MUC1 receptor subunit in gene regulation
    D Kufe
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Oncogene 29:5663-6. 2010
    ..In this issue of Oncogene and in concert with published work, Behrens et al. report that the MUC1 receptor subunit activates genes involved in invasion, angiogenesis and metastasis...
  8. ncbi request reprint Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology
    Donald Kufe
    Dana Farber Cancer Institute, Harvard Medical School Boston, Massachusetts USA
    Cancer Biol Ther 2:326-9. 2003
    ..Based on these findings, radiation in combination with intratumoral administration of a second generation Ad.EGR-TNF (TNFerade) has completed Phase I evaluation and has entered Phase II clinical trials...
  9. ncbi request reprint Inhibition of c-Abl with STI571 attenuates stress-activated protein kinase activation and apoptosis in the cellular response to 1-beta-D-arabinofuranosylcytosine
    Deepak Raina
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Pharmacol 61:1489-95. 2002
    ..These findings demonstrate that STI571 down-regulates c-Abl-mediated signals that target the mitochondria in the apoptotic response to ara-C...
  10. ncbi request reprint Targeting the human MUC1 oncoprotein: a tale of two proteins
    Donald W Kufe
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Biol Ther 7:81-4. 2008
  11. ncbi request reprint Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents
    Jian Ren
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 5:163-75. 2004
    ..These findings indicate that MUC1 attenuates the apoptotic response to DNA damage and that this oncoprotein confers resistance to genotoxic anticancer agents...
  12. ncbi request reprint Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62
    Yumei Leng
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 282:19321-30. 2007
    ..These findings indicate that the MUC1-C oncoprotein is imported to the nucleus by a pathway involving Nup62...
  13. ncbi request reprint MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation
    Lei Huang
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Biol Ther 2:702-6. 2003
    ..These findings support a model in which the MUC1 functions as a transforming protein by coactivating transcription of Wnt target genes...
  14. ncbi request reprint MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin
    Lei Huang
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 65:10413-22. 2005
    ..These findings indicate that MUC1 promotes transformation, at least in part, by blocking GSK3beta-mediated phosphorylation and thereby degradation of beta-catenin...
  15. pmc MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling
    Jian Ren
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Mol Cancer Res 4:873-83. 2006
    ..These findings indicate that FGF1 induces phosphorylation of MUC1 on YEKV and thereby activates two distinct pathways: (a) nuclear localization of MUC1 and beta-catenin and (b) delivery of MUC1 to mitochondria by HSP90...
  16. ncbi request reprint MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress
    Li Yin
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 279:45721-7. 2004
    ..These findings indicate that MUC1 regulates the FOXO3a signaling pathway in a survival response to oxidative stress...
  17. ncbi request reprint Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses
    David Avigan
    Beth Israel Deaconess Medical Center and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 10:4699-708. 2004
    ..We have conducted a Phase I trial in which patients with metastatic breast and renal cancer were treated with a vaccine prepared by fusing autologous tumor and DCs...
  18. ncbi request reprint Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein
    Yongqing Li
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Mol Cancer Res 1:765-75. 2003
    ..These findings demonstrate that MUC1 functions in cross talk between ErbB2 and Wnt pathways by acting as a shuttle for HRG-induced nucleolar targeting of gamma-catenin...
  19. ncbi request reprint Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells
    Alexandra Zoltan-Jones
    Department of Anatomy and Cellular Biology, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Biol Chem 278:45801-10. 2003
    ..Thus, increased expression of hyaluronan is sufficient to induce epithelial-mesenchymal transition and acquisition of transformed properties in phenotypically normal epithelial cells...
  20. pmc Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells
    Baldev Vasir
    Dana Farber Cancer Institute, Dana Farber Harvard Cancer Center, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Immunol 181:808-21. 2008
    ..In contrast, exposure to TLR agonists, stimulatory cytokines, and anti-CD3/CD28 enhances vaccine efficacy by limiting the regulatory T cell response and promoting expansion of activated effector cells...
  21. ncbi request reprint Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma
    David E Avigan
    Beth Israel Deaconess Medical Center and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    J Immunother 30:749-61. 2007
    ..Vaccination of patients with RCC with allogeneic DC/tumor fusions was feasible, well tolerated, and resulted in immunologic and clinical responses in a subset of patients...
  22. ncbi request reprint Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts
    Jianlin Gong
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Leuk Res 28:1303-12. 2004
    ..The FC/AML induced greater T cell proliferation and CTL activity against autologous AML blasts (9/10 cases) as compared to NAD-DC. FC/AML may thus represent a promising strategy for DC-based immunotherapy of patients with AML...
  23. ncbi request reprint Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid
    Takashi Ikeda
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Mol Cancer Ther 3:39-45. 2004
    ..These results suggest that CDDO compounds have potential as new agents for the treatment of MM...
  24. ncbi request reprint Dendritic cell fusion vaccines for cancer immunotherapy
    Jacalyn Rosenblatt
    Hematologic Malignancy Bone Marrow Transplant Program, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, KS 121, Boston, MA 02215, USA
    Expert Opin Biol Ther 5:703-15. 2005
    ..Preliminary results demonstrate that generation of a vaccine is feasible and that vaccination is associated with minimal toxicity. Immunological and clinical responses have been found in a subset of patients...
  25. ncbi request reprint The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice
    Shigeo Koido
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    J Immunol 168:2111-7. 2002
    ..Moreover, CD4+ T cells activated by FC/MUC1 were multifunctional effectors that produced IL-2, IFN-gamma, IL-4, and IL-10. These findings indicate that both CD4+ and CD8+ T cells can be primed in vivo by FC/MUC1 immunization...
  26. pmc Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28
    Jacalyn Rosenblatt
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Immunother 33:155-66. 2010
    ..These findings indicate that stimulation with DC/tumor fusions provides a unique platform for subsequent expansion with anti-CD3/CD28 in adoptive T-cell therapy of cancer...
  27. ncbi request reprint Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation
    Baldev Vasir
    Department of Medical Oncology and Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 129:687-700. 2005
    ..These findings demonstrate that tumour cell fusion induces DC maturation and the development of an activated phenotype necessary for their effectiveness as cancer vaccines...
  28. ncbi request reprint The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance
    Takashi Ikeda
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 63:5551-8. 2003
    ..In concert with these results, CDDO-induced apoptosis is also abrogated by N-acetyl-L-cysteine and GSH. These findings demonstrate that CDDO and its derivatives disrupt intracellular redox balance and thereby induce apoptosis...
  29. ncbi request reprint Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571
    Shailendra Kumar
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Pharmacol 63:276-82. 2003
    ..These findings indicate that inhibition of c-Abl signaling by STI571 attenuates mitochondrial dysfunction and cell death in the cellular response to oxidative stress...
  30. ncbi request reprint c-Abl tyrosine kinase regulates caspase-9 autocleavage in the apoptotic response to DNA damage
    Deepak Raina
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 280:11147-51. 2005
    ..These findings indicate that caspase-9 autoprocessing is regulated by c-Abl in the apoptotic response to genotoxic stress...
  31. ncbi request reprint 2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid, a small molecule isocoumarin, potentiates dexamethasone-induced apoptosis of human multiple myeloma cells
    Naoki Agata
    ILEX Products, Inc, Boston, Massachusetts 02115, USA
    Cancer Res 64:8512-6. 2004
    ..These findings indicate that NM-3 may be effective in combination with dexamethasone in the treatment of MM...
  32. pmc Protein kinase Cdelta is responsible for constitutive and DNA damage-induced phosphorylation of Rad9
    Kiyotsugu Yoshida
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    EMBO J 22:1431-41. 2003
    ..These findings demonstrate that PKCdelta is responsible for the regulation of Rad9 in the Hus1-Rad1 complex and in the apoptotic response to DNA damage...
  33. pmc Perturbation of hyaluronan interactions inhibits malignant properties of glioma cells
    Jeanine A Ward
    Department of Anatomy and Cellular Biology, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Am J Pathol 162:1403-9. 2003
    ..Based on our findings, we conclude that endogenous hyaluronan interactions are essential for these two fundamental malignant properties of glioma cells...
  34. doi request reprint Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors
    Geoffrey I Shapiro
    Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 17:3431-42. 2011
    ..Two phase I dose-escalation studies were conducted to determine the maximum tolerated dose (MTD) and safety profile of the G(2) checkpoint abrogator CBP501, as a single agent and in combination with cisplatin...
  35. ncbi request reprint Dendritic cells induce MUC1 expression and polarization on human T cells by an IL-7-dependent mechanism
    Baldev Vasir
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 174:2376-86. 2005
    ..These findings indicate that DC-mediated activation of Ag-specific T cells is associated with induction and polarization of MUC1 expression by an IL-7-dependent mechanism...
  36. pmc Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells
    Dongshu Chen
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Immunology 109:300-7. 2003
    ..These results indicate that immunization with FC/MUC1 can generate an anti-MUC1 response that is sufficient to delay the development of spontaneous mammary carcinomas and control tumour progression in MMT mice...
  37. pmc c-Abl tyrosine kinase regulates the human Rad9 checkpoint protein in response to DNA damage
    Kiyotsugu Yoshida
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Cell Biol 22:3292-300. 2002
    ..These findings indicate that Rad9 is regulated by a c-Abl-dependent mechanism in the apoptotic response to genotoxic stress...
  38. ncbi request reprint Catalase activity is regulated by c-Abl and Arg in the oxidative stress response
    Cheng Cao
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 278:29667-75. 2003
    ..These findings indicate that c-Abl and Arg regulate catalase and that this signaling pathway is of importance to apoptosis in the oxidative stress response...
  39. ncbi request reprint Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress
    Li Yin
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 278:35458-64. 2003
    ..These results support a model in which activation of MUC1 by oxidative stress provides a protective function against increased intracellular oxidant levels and ROS-induced apoptosis...
  40. ncbi request reprint Lyn tyrosine kinase inhibits nuclear export of the p53 tumor suppressor
    Xinping Ren
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Biol Ther 1:703-8. 2002
    ..In concert with these results, Lyn reverses Mdm2-mediated degradation of p53 and increases p53-dependent apoptosis. Our findings support a previously undefined role for nuclear Lyn in both activation and Mdm2-mediated regulation of p53...
  41. ncbi request reprint Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12
    Jianlin Gong
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Blood 99:2512-7. 2002
    ..These findings demonstrate that immunization with FC/4TOO fusion cells and IL-12 potentiates antitumor immunity and the treatment of murine multiple myeloma...
  42. ncbi request reprint Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors
    Jeffrey G Supko
    Massachusetts General Hospital, Dana Farber Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Cancer Res 9:5178-86. 2003
    ..A Phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities, and pharmacokinetic behavior of KRN5500 given as a 1-h i.v. infusion for 5 consecutive days every 3 weeks...
  43. ncbi request reprint Mucin 1 oncoprotein blocks hypoxia-inducible factor 1alpha activation in a survival response to hypoxia
    Li Yin
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 282:257-66. 2007
    ..Importantly, MUC1 also blocks hypoxia-induced apoptosis and necrosis by suppressing accumulation of ROS. These findings indicate that MUC1 attenuates HIF-1alpha activation in a survival response to hypoxic stress...
  44. pmc MUC1 oncoprotein is a druggable target in human prostate cancer cells
    Maya Datt Joshi
    Dana Farber Cancer Institute, Dana 830, Boston, MA 02115, USA
    Mol Cancer Ther 8:3056-65. 2009
    ..These findings indicate that certain prostate cancer cells are dependent on MUC1-C for growth and survival and that directly targeting MUC1-C results in their death in vitro and in tumor models...
  45. ncbi request reprint Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene
    Xiaolong Wei
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Cancer Res 67:1853-8. 2007
    ..These findings indicate that overexpression of MUC1, as found in human breast cancer cells, is of functional importance to repression of the p53 gene...
  46. pmc MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor
    Rehan Ahmad
    Dana Farber Cancer Institute, Harvard Medical School and Genus Oncology, Boston, Massachusetts 02115, USA
    Cancer Res 69:7013-21. 2009
    ..These findings indicate that MUC1-C is a direct activator of NF-kappaB p65 and that an inhibitor of MUC1 function is effective in blocking activation of the NF-kappaB pathway...
  47. pmc MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway
    Deepak Raina
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Biol Ther 7:1959-67. 2008
    ..We also show that the MUC1(Y60F) mutant functions as dominant negative inhibitor of tumorigenicity. These findings indicate that the oncogenic function of MUC1 is conferred by suppressing activation of the ARF-MDM2-p53 pathway...
  48. ncbi request reprint Evolution of the human MUC1 oncoprotein
    Sekhar Duraisamy
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Int J Oncol 31:671-7. 2007
    ..These findings indicate that both the MUC1-N and MUC1-C subunits evolved from secreted gel-forming mucins and that the MUC1-CD oncogenic function emerged by diversification after evolution from MUC5B...
  49. pmc MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells
    Takeshi Kawano
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Int J Oncol 33:153-9. 2008
    ..These findings indicate that MUC1 activates the beta-catenin and NF-kappaB pathways in multiple myeloma cells and contributes to their growth and survival...
  50. ncbi request reprint A novel isocoumarin derivative induces mitotic phase arrest and apoptosis of human multiple myeloma cells
    Takeshi Kawano
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115 USA
    Cancer Chemother Pharmacol 59:329-35. 2007
    ..The isocoumarin NM-3 reverses resistance of human multiple myeloma (MM) cells to dexamethasone and is in clinical trials. In the present work, the NM-3 analog, 185322, has been studied for activity against MM cells...
  51. ncbi request reprint MUC1 oncoprotein stabilizes and activates estrogen receptor alpha
    Xiaolong Wei
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Cell 21:295-305. 2006
    ..These findings provide evidence that MUC1 stabilizes ERalpha and that this oncoprotein is of importance to the activation of ERalpha function...
  52. ncbi request reprint p73beta is regulated by protein kinase Cdelta catalytic fragment generated in the apoptotic response to DNA damage
    Jian Ren
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Biol Chem 277:33758-65. 2002
    ..These findings demonstrate that cleavage of PKCdelta to PKCdeltaCF induces apoptosis by a mechanism in part dependent on PKCdeltaCF-mediated phosphorylation of the p73beta Ser-289 site...
  53. ncbi request reprint Activation of SAPK/JNK signaling by protein kinase Cdelta in response to DNA damage
    Kiyotsugu Yoshida
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 277:48372-8. 2002
    ..These findings indicate that PKCdelta functions in the activation of SAPK through a Lyn --> PKCdelta --> MEKK1 --> MKK7 --> SAPK signaling cascade in response to DNA damage...
  54. ncbi request reprint DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7
    Yongqing Li
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Biol Ther 2:187-93. 2003
    ..These findings indicate that IL-7 regulates MUC1 expression and function in multiple myeloma cells...
  55. ncbi request reprint Glutathione peroxidase 1 is regulated by the c-Abl and Arg tyrosine kinases
    Cheng Cao
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 278:39609-14. 2003
    ..Our findings provide the first evidence that GPx1 is regulated by a signaling pathway that is activated in the oxidative stress response...
  56. ncbi request reprint Interaction of human MUC1 and beta-catenin is regulated by Lck and ZAP-70 in activated Jurkat T cells
    Quan Li
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02482, USA
    Biochem Biophys Res Commun 315:471-6. 2004
    ..These findings indicate that MUC1 functions as a substrate for Lck and ZAP-70 in activated Jurkat T cells and that MUC1 integrates T cell receptor signaling with the beta-catenin pathway...
  57. ncbi request reprint MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling
    Rehan Ahmad
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Nat Cell Biol 9:1419-27. 2007
    ..These findings indicate that MUC1 is important for physiological activation of IKKbeta and that overexpression of MUC1, as found in human cancers, confers sustained induction of the IKKbeta-NF-kappaB p65 pathway...
  58. ncbi request reprint Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response
    Xiaolong Wei
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Cell 7:167-78. 2005
    ..These findings indicate that MUC1 regulates p53-responsive genes and thereby cell fate in the genotoxic stress response...
  59. pmc Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells
    Deepak Raina
    Dana Farber Cancer Institute, 44 Binney Street, Dana 830, Boston, MA 02115, USA
    Mol Cancer Ther 10:806-16. 2011
    ..These findings indicate that NSCLC cells are dependent on MUC1-C both for activation of the PI3K → Akt pathway and for survival...
  60. pmc Mucin 1 C-terminal subunit oncoprotein is a target for small-molecule inhibitors
    Yongchun Zhou
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Mol Pharmacol 79:886-93. 2011
    ..These findings represent the first demonstration that the MUC1-C cytoplasmic domain is a target for the development of small-molecule inhibitors...
  61. ncbi request reprint Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily
    Joseph P Eder
    Division of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 20:3772-84. 2002
    ..To perform a phase I trial of recombinant human endostatin (rhEndostatin; EntreMed, Rockville, MD) given as a daily 20-minute intravenous (IV) injection in adult patients with refractory solid tumors...
  62. ncbi request reprint Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling
    Jian Ren
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 277:17616-22. 2002
    ..These findings support a novel role for PKCdelta in regulating the interaction between MUC1 and the beta-catenin signaling pathway...
  63. pmc MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage
    Deepak Raina
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    EMBO J 25:3774-83. 2006
    ..These findings indicate that MUC1 sequesters c-Abl in the cytoplasm and thereby inhibits apoptosis in the response to genotoxic anticancer agents...
  64. pmc miR-1226 targets expression of the mucin 1 oncoprotein and induces cell death
    Caining Jin
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Int J Oncol 37:61-9. 2010
    ..These findings indicate that expression of the MUC1 oncoprotein is downregulated by miR-1226 and that miR-1226 thereby functions as a tumor suppressor by promoting the induction of cell death...
  65. ncbi request reprint Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179
    Rehan Ahmad
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 281:35764-9. 2006
    ..These findings indicate that CDDO and CDDO-Me directly block IKKbeta activity and thereby the NF-kappaB pathway by interacting with Cys-179 in the IKKbeta activation loop...
  66. pmc Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function
    Li Yin
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115 6084, USA
    Mol Pharmacol 78:166-74. 2010
    ..These findings indicate that multiple myeloma cells are dependent on intact MUC1-C function for constitutive activation of the canonical NF-kappaB pathway and for their growth and survival...
  67. ncbi request reprint The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts
    Deepak Raina
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Biol Chem 279:20607-12. 2004
    ..Similar results were obtained with the anti-cancer agent, gemcitabine. These findings indicate that expression of MUC1 in 3Y1 cells activates the anti-apoptotic PI3K/Akt and Bcl-x(L) pathways...
  68. pmc MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8
    Naoki Agata
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 68:6136-44. 2008
    ....
  69. pmc Transcriptional control of viral gene therapy by cisplatin
    James O Park
    Department of Surgery, University of Chicago, Chicago, Illinois, USA
    J Clin Invest 110:403-10. 2002
    ..Egr.TNF.11D and cisplatin, compared with either agent alone. Chemo-inducible cancer gene therapy thus provides a means to control transgene expression while enhancing the effectiveness of commonly used chemotherapeutic agents...
  70. ncbi request reprint Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity
    Carlos A Lopez
    Department of Radiation and Cellular Oncology, University of Chicago Hospitals, Center for Advanced Medicine, Room 1329, Mail Code 9006, 5758 South Maryland Avenue, Chicago, IL 60637, USA
    Mol Cancer Ther 3:1167-75. 2004
    ..Egr-TNF.11D as compared with either agent alone. These data show that Ad.Egr-TNF.11D is activated by diverse anticancer drugs...
  71. ncbi request reprint Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy
    Ralph R Weichselbaum
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA
    Lancet Oncol 3:665-71. 2002
    ..This review summarises the rationale, mechanistic basis, preclinical data, and preliminary clinical findings for this new treatment model...
  72. ncbi request reprint Chemo-inducible gene therapy
    James J Mezhir
    Department of Surgery, University of Chicago Hospitals, Chicago, Illinois 60637, USA
    Anticancer Drugs 16:1053-8. 2005
    ..The development of chemo-inducible gene therapy has numerous implications for the treatment of both localized and metastatic disease in patients with solid tumors...
  73. ncbi request reprint Tumor production of angiostatin is enhanced after exposure to TNF-alpha
    Helena J Mauceri
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
    Int J Cancer 97:410-5. 2002
    ..These studies support a model in which the antiangiogenic effects of TNF-alpha on the tumor microvasculature are mediated by generation of angiostatin...
  74. ncbi request reprint Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance
    Vinay K Gupta
    University of Chicago, Department of Surgery, Illinois, USA
    Cancer J 8:47-54. 2002
    ..Vascular endothelial growth factor (VEGF) is an important mediator of endothelial cell proliferation and survival. The purpose of the present studies was to investigate the role of VEGF in the tumor response to ionizing radiation...
  75. ncbi request reprint Manganese superoxide dismutase (SOD2) inhibits radiation-induced apoptosis by stabilization of the mitochondrial membrane
    Michael W Epperly
    Department of Radiation Oncology, University of Pittsburgh Cancer Institute, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
    Radiat Res 157:568-77. 2002
    ....
  76. ncbi request reprint Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma
    Bakhtiar Yamini
    Department of Surgery, Section of Neurosurgery and Department of Radiation and Cellular Oncology, Pritzker School of Medicine, The University of Chicago, Chicago, Illinois 60637, USA
    Cancer Res 64:6381-4. 2004
    ..05). In conclusion, combination treatment with transcriptionally activated intratumoral TNF-alpha and systemic temozolomide significantly prolongs survival in an experimental glioblastoma multiforme model...
  77. ncbi request reprint Diverse TNFalpha-induced death pathways are enhanced by inhibition of NF-kappaB
    Mukta Katdare
    Department of Surgery, Section of General Surgery, University of Chicago Hospitals, Chicago, IL 60637, USA
    Int J Oncol 31:1519-28. 2007
    ....
  78. ncbi request reprint A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities
    Arno J Mundt
    University of Chicago Medical Center, Chicago, Illinois, USA
    Clin Cancer Res 10:5747-53. 2004
    ..The objective of this study was to assess the tolerance of combining TNFerade and radiation therapy in patients with soft tissue sarcomas of the extremity...
  79. ncbi request reprint Forphenicinol enhances the antitumor effects of cyclophosphamide in a model of squamous cell carcinoma
    Kevin T Murphy
    Department of Radiation and Cellular Oncology, University of Chicago, 5758 S Maryland Avenue, MC1105, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 56:317-21. 2005
    ..001), CPA alone (P=0.002) and IR alone (P=0.002). Due to its low toxicity profile, FPL may be combined with CPA, IR and other cytotoxic therapies to potentially enhance the therapeutic ratio...
  80. ncbi request reprint Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma
    Noopur Raje
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Br J Haematol 125:343-52. 2004
    ..These studies therefore demonstrated that MM/DC FC can trigger an autologous immune response to MM cells and formed the framework for a clinical trial currently underway...
  81. ncbi request reprint Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint
    Shi Ken Sha
    CanBas Co Ltd, Makiya Building 5F, 9 Tooriyoko cho, Numazu 410 0891, Japan
    Mol Cancer Ther 6:147-53. 2007
    ..This report also shows the usefulness of the cell cycle phenotype-based protocol for identifying G(2) checkpoint-abrogating compounds as well as the potential of peptide-based compounds as focused multitarget inhibitors...
  82. ncbi request reprint Angiostatin potentiates cyclophosphamide treatment of metastatic disease
    Helena J Mauceri
    Department of Radiation and Cellular Oncology, Duchossois Center for Advanced Medicine, 5758 S Maryland Avenue, MC 9006, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 50:412-8. 2002
    ..We studied the effects of AS and CPA on the stages of angiogenesis employing in vitro assays...

Research Grants64

  1. Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer
    Donald Kufe; Fiscal Year: 2009
    ..Our proposed research on MUC1 should provide a better understanding of the causes of breast cancer and potentially new opportunities for treatment. ..
  2. DIFFERENTIATING AGENTS IN HEMATOLOGIC MALIGNANCIES
    Donald Kufe; Fiscal Year: 2004
    ..abstract_text> ..
  3. MOLECULAR MECHANISMS OF ARA-C THERAPY IN MAN
    Donald Kufe; Fiscal Year: 2003
    ..abstract_text> ..
  4. DIFFERENTIATING AGENTS IN HEMATOLOGIC MALIGNANCIES
    Donald Kufe; Fiscal Year: 2003
    ..abstract_text> ..
  5. Regulation of Oxidative Stress Response by c-Abl and Arg
    Donald Kufe; Fiscal Year: 2003
    ..abstract_text> ..
  6. MOLECULAR MECHANISMS OF ARA-C THERAPY IN MAN
    Donald Kufe; Fiscal Year: 2002
    ..abstract_text> ..
  7. MOLECULAR REGULATION OF SIGNALING BY IONIZING RADIATION
    Donald Kufe; Fiscal Year: 2002
    ....
  8. MOLECULAR MECHANISMS OF ARA-C THERAPY IN MAN
    Donald Kufe; Fiscal Year: 2001
    ..abstract_text> ..
  9. DIFFERENTIATING AGENTS IN HEMATOLOGIC MALIGNANCIES
    Donald Kufe; Fiscal Year: 2002
    ....
  10. MOLECULAR MECHANISMS OF ARA-C THERAPY IN MAN
    Donald Kufe; Fiscal Year: 2001
    ..3) To determine the effects of ara-C-induced c-Abl and SAP kinase signaling on the regulation of cyclin function. 4) To define the relationship between ara-C-induced signaling, proteolytic activation of PKC delta and apoptosis. ..
  11. MOLECULAR REGULATION OF SIGNALING BY IONIZING RADIATION
    Donald Kufe; Fiscal Year: 2000
    ....
  12. MOLECULAR MECHANISMS OF ARA-C THERAPY IN MAN
    Donald Kufe; Fiscal Year: 2000
    ..3) To determine the effects of ara-C-induced c-Abl and SAP kinase signaling on the regulation of cyclin function. 4) To define the relationship between ara-C-induced signaling, proteolytic activation of PKC delta and apoptosis. ..
  13. Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer
    Donald Kufe; Fiscal Year: 2004
    ..abstract_text> ..
  14. MOLECULAR MECHANISMS OF ARA-C THERAPY IN MAN
    Donald Kufe; Fiscal Year: 2004
    ..abstract_text> ..
  15. Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer
    Donald W Kufe; Fiscal Year: 2010
    ..Our proposed research on MUC1 should provide a better understanding of the causes of breast cancer and potentially new opportunities for treatment. ..
  16. DIFFERENTIATING AGENTS IN HEMATOLOGIC MALIGNANCIES
    Donald W Kufe; Fiscal Year: 2010
    ..The proposed work will expand our understanding of how agents that disrupt redox balance induce terminal differentiation in the laboratory and in patients on clinical trials. ..
  17. Phase I Trials of New Anti-Cancer Agents
    Donald Kufe; Fiscal Year: 2007
    ..1, ICAM-1 and LFA-3). ..
  18. Regulation of Oxidative Stress Response by c-Abl and Arg
    Donald Kufe; Fiscal Year: 2007
    ..abstract_text> ..
  19. Regulation of Oxidative Stress Response by c-Abl and Arg
    Donald Kufe; Fiscal Year: 2006
    ..abstract_text> ..
  20. DIFFERENTIATING AGENTS IN HEMATOLOGIC MALIGNANCIES
    Donald Kufe; Fiscal Year: 2006
    ..abstract_text> ..
  21. MOLECULAR MECHANISMS OF ARA-C THERAPY IN MAN
    Donald Kufe; Fiscal Year: 2005
    ..abstract_text> ..
  22. Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer
    Donald Kufe; Fiscal Year: 2005
    ..abstract_text> ..
  23. DIFFERENTIATING AGENTS IN HEMATOLOGIC MALIGNANCIES
    Donald Kufe; Fiscal Year: 2005
    ..abstract_text> ..
  24. MOLECULAR REGULATION OF SIGNALING BY IONIZING RADIATION
    Donald Kufe; Fiscal Year: 1999
    ..3) To study functional interactions between Lyn and Cdc2 in irradiated cells. 4) To define IR-induced nuclear signals responsible for activation of c- jun transcription. ..
  25. DIFFERENTIATING AGENTS IN HEMATOLOGIC MALIGNANCIES
    Donald Kufe; Fiscal Year: 1999
    ....
  26. MOLECULAR MECHANISMS OF ARA-C THERAPY IN MAN
    Donald Kufe; Fiscal Year: 1999
    ..3) To determine the effects of ara-C-induced c-Abl and SAP kinase signaling on the regulation of cyclin function. 4) To define the relationship between ara-C-induced signaling, proteolytic activation of PKC delta and apoptosis. ..
  27. MOLECULAR MECHANISMS OF ARA-C THERAPY IN MAN
    Donald Kufe; Fiscal Year: 1992
    ....
  28. MOLECULAR REGULATION OF C-JUN BY IONIZING RADIATION
    Donald Kufe; Fiscal Year: 1992
    ....
  29. DIFFERENTIATING AGENTS IN HEMATOLOGIC MALIGNANCIES
    Donald Kufe; Fiscal Year: 1992
    ..This work should also contribute to our understanding of the in vivo therapeutic effects of agents that induce differentiation in vitro...
  30. DIFFERENTIATING AGENTS IN HEMATOLOGIC MALIGNANCIES
    Donald Kufe; Fiscal Year: 1991
    ..This work should also contribute to our understanding of the in vivo therapeutic effects of agents that induce differentiation in vitro...
  31. MOLECULAR MECHANISMS OF ARA-C THERAPY IN MAN
    Donald Kufe; Fiscal Year: 1993
    ....
  32. MOLECULAR MECHANISMS OF ARA-C THERAPY IN MAN
    Donald Kufe; Fiscal Year: 1990
    ....
  33. MOLECULAR MECHANISMS OF ARA-C THERAPY IN MAN
    Donald Kufe; Fiscal Year: 1991
    ....
  34. Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer
    Donald Kufe; Fiscal Year: 2009
    ..Our proposed research on MUC1 should provide a better understanding of the causes of breast cancer and potentially new opportunities for treatment. ..
  35. DIFFERENTIATING AGENTS IN HEMATOLOGIC MALIGNANCIES
    Donald Kufe; Fiscal Year: 2002
    ..abstract_text> ..
  36. MOLECULAR REGULATION OF SIGNALING BY IONIZING RADIATION
    Donald Kufe; Fiscal Year: 2001
    ....
  37. Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer
    Donald Kufe; Fiscal Year: 2006
    ..abstract_text> ..
  38. DIFFERENTIATING AGENTS IN HEMATOLOGIC MALIGNANCIES
    Donald Kufe; Fiscal Year: 2001
    ....
  39. Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer
    Donald Kufe; Fiscal Year: 2002
    ..abstract_text> ..
  40. Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer
    Donald Kufe; Fiscal Year: 2003
    ..abstract_text> ..